← Immunocore Holdings plc (IMCR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immunocore Holdings plc (IMCR)
Biological Products, (No Diagnostic Substances) · market cap $1.6B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Immunocore Holdings plc (IMCR) is a clinical-stage biopharmaceutical company with a market cap of ~$1.78B and a pipeline anchored by tebentafusp (approved or late-stage for uveal melanoma) and brenetafusp, its lead asset now in Phase 3 for select advanced solid tumors. The company generated $400M in revenue in 2025, carries $452.7M in cash (roughly 8+ years of runway), and faces two near-term Phase 2 readouts by year-end 2026.
The catalyst path
- 2026-10-15 (est.)Phase 2 · Brenetafuspimp 7/10
- 2026-11-05 (est.)Earningsimp 5/10
- 2026-11-30 (est.)Phase 2 · IMC-R117Cimp 7/10
- 2026-12-30 (est.)Phase 2 · Tebentafuspimp 7/10
- 2027-08-15 (est.)Phase 2 · Tebentafusp-Tebnimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Brenetafusp | Phase 3 | Select Advanced Solid Tumors |
| IMC-R117C | Phase 2 | Cancer |
| Tebentafusp | Phase 3 | Advanced Melanoma |
| IMCgp100 | Phase 2 | Uveal Melanoma |
| Tebentafusp-Tebn | Phase 2 | Locally Advanced Unresectable Uveal Melanoma |
Price & technical context
3-month
-6.9%
6-month
-3.6%
12-month
-17.3%
52-wk range
$27.79–$40.22
vs 50-day MA
-12.5%
vs 200-day MA
-7.6%
Realized vol
36.7%
Max drawdown
-30.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMCR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.